A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results

被引:24
|
作者
Lambert, J. [1 ]
Bostoen, J. [1 ]
Geusens, B. [1 ]
Bourgois, J. [2 ]
Boone, J. [2 ]
De Smedt, D. [3 ]
Annemans, L. [3 ]
机构
[1] Ghent Univ Hosp, Dept Dermatol, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Ctr Sports Med, B-9000 Ghent, Belgium
[3] Ghent Univ Hosp, Dept Publ Hlth, B-9000 Ghent, Belgium
关键词
Education; Skin diseases; ATOPIC-DERMATITIS; TRAINING-PROGRAM; PSORIASIS; STRESS; MANAGEMENT; ADULTS; INDEX; ITCH; DERMATOLOGY; LIFE;
D O I
10.1007/s00403-010-1082-z
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Chronic inflammatory skin disorders have a major impact on the patients' health related quality of life. Preliminary studies to date have suggested that additional educational and psychological training programmes may be effective in the management of chronic skin diseases, although more rigid methodology is needed. Our purpose was to investigate the effect on quality of life of a novel multidisciplinary educational programme for patients, 18 years or older, with chronic skin diseases. The 12-week intervention encompasses cognitive education on skin and general health issues, and stress-reducing techniques. Quality of life questionnaires were used to assess the participants at baseline and at the end of the program. These comprehend Dermatology Life Quality Index (DLQI), Skindex-29, Psoriasis Disability Index (PDI) and Quality of Life Index for Atopic Dermatitis (QoLIAD). Fifty-five patients participated in six programmes since 2006. Forty-three patients completed the programme. Overall, compared to baseline, DLQI (n = 39) improved by 5.64 points (p < 0.001; SD +/- 6.09), Skindex-29 (n = 27) by 19.67 points (p < 0.001; SD +/- 17.37), PDI (n = 9) improved by 7.44 points (p = 0.019; SD +/- 7.60) and QoLIAD (n = 13) improved by 4.39 points (p = 0.036; SD +/- 6.69) by the end of the intervention. Preliminary results show that the quality of life of the patients with chronic skin diseases improved significantly after participation to the programme. These positive initial results are stimulating to set up a prospective controlled randomised trial investigating the impact on quality of life, the clinical efficacy and the cost-effectiveness of this educational intervention programme.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 40 条
  • [31] Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre "Stop Imatinib" (STIM) Study
    Mahon, Francois-Xavier
    Huguet, Francoise
    Guilhot, Francois
    Legros, Laurence
    Nicolini, Franck E.
    Charbonnier, Aude
    Guerci, Agnes
    Rea, Delphine
    Varet, Bruno R.
    Gardembas, Martine
    Guilhot, Joelle
    Etienne, Gabriel
    Milpied, Noel-Jean
    Aton, Emilie
    Reiffers, Josy
    Rousselot, Philippe
    BLOOD, 2008, 112 (11) : 76 - 76
  • [32] Integrated Management of Patients with Chronic Inflammatory Bowel Disease in the Rhine-Main Region: Results of the First Integrated Health-Care Project IBD in Germany
    Blumenstein, I.
    Tacke, W.
    Filmann, N.
    Zosel, C.
    Bock, H.
    Heuzeroth, V.
    Zeuzem, S.
    Schroeder, O.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (07): : 613 - 618
  • [33] Behaviour change in chronic respiratory disease patients through health care worker delivered theory of planned behaviour-based educational intervention: results from a pilot feasibility study
    Isaac, Rita
    Paul, Biswajit
    Das, Deepa
    Mani, Thenmozhi
    Babu, Malvika
    Norrie, John
    Grant, Liz
    Weller, David
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [34] Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry
    Reguiai, Ziad
    Becherel, Pierre Andre
    Perrot, Jean Luc
    Fougerousse, Anne Claire
    Begon, Edouard
    Poreaux, Claire
    Boulard, Claire
    Chaby, Guillaume
    Fite, Charlotte
    Zaraa, Ines
    Lons-danic, Dominique
    Liegeon, Anne -Laure
    Parier, Josiane
    Quiles-tsimaratos, Nathalie
    David, Laurene
    OMCCI Grp
    ACTA DERMATO-VENEREOLOGICA, 2023, 103
  • [35] Association Between Self-Reported Protective Behavior and Heat-Associated Health Complaints Among Patients With Chronic Diseases in Primary Care: Results of the CLIMATE Pilot Cohort Study
    Jordan, Arne
    Nothacker, Julia
    Paucke, Valentina
    Hager, Klaus Heinz
    Hueber, Susann
    Karimzadeh, Arian
    Koetter, Thomas
    Loeffler, Christin
    Mueller, Beate Sigrid
    Tajdar, Daniel
    Luehmann, Dagmar
    Scherer, Martin
    Schaefer, Ingmar
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2024, 10
  • [36] Proof of Concept of a 6-Month Person-Oriented Exercise Intervention 'MultiPill-Exercise' among Patients at Risk of or with Multiple Chronic Diseases: Results of a One-Group Pilot Trial
    Schweda, Simone
    Munz, Barbara
    Burgstahler, Christof
    Niess, Andreas Michael
    Roesel, Inka
    Sudeck, Gorden
    Krauss, Inga
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (15)
  • [37] Quality of patch testing patient's own material in patients with suspected occupational skin diseases throughout Germany: Interim results of the German Social Accident Insurance (DGUV) research project FB 317b
    Symanzik, Cara
    Dicke, Katja
    Weinert, Patricia
    Weisshaar, Elke
    Brans, Richard
    Skudlik, Christoph
    John, Swen M.
    Obermeyer, Lara
    CONTACT DERMATITIS, 2024, 90 (03) : 291 - 298
  • [38] A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study
    Hagihara, Maki
    Iriyama, Noriyoshi
    Yoshida, Chikashi
    Fujisawa, Shin
    Wakita, Hisashi
    Chiba, Shigeru
    Takezako, Naoki
    Kawakami, Kimihiro
    Okamoto, Shinichiro
    Inokuchi, Koiti
    Ohyashiki, Kazuma
    Kumagai, Takashi
    Taguchi, Jun
    Yano, Shingo
    Igarashi, Tadahiko
    Kouzai, Yasuji
    Sakamoto, Junichi
    Morita, Satoshi
    Sakamaki, Hisashi
    BLOOD, 2014, 124 (21)
  • [39] Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
    Smolej, Lukas
    Brychtova, Yvona
    Cmunt, Eduard
    Doubek, Michael
    Spacek, Martin
    Belada, David
    Simkovic, Martin
    Stejskal, Lukas
    Zygulova, Irena
    Urbanova, Renata
    Brejcha, Martin
    Zuchnicka, Jana
    Mocikova, Heidi
    Kozak, Tomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 769 - 778
  • [40] First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Garcia-Manero, Guillermo
    Ritchie, Ellen K.
    Walsh, Katherine
    Savona, Michael
    Kropf, Patricia
    O'Connell, Casey
    Tibes, Raoul
    Daver, Naval G.
    Jabbour, Elias
    Lunin, Scott
    Rosenblat, Todd L.
    Yee, Karen
    Stock, Wendy
    Griffiths, Elizabeth A.
    Mace, Joseph R.
    Podoltsev, Nikolai A.
    Berdeja, Jesus G.
    Issa, Jean-Pierre
    Chung, Woonbok
    Naim, Sue
    Taverna, Pietro
    Hao, Yong
    Azab, Mohammad
    Kantarjian, Hagop M.
    Roboz, Gail J.
    BLOOD, 2014, 124 (21)